No Data
GENSCRIPT BIO (01548) issued a total of 2.216 million shares on January 3 under the exercised Options plan.
GENSCRIPT BIO (01548) announced that on January 3, 2025, it will act according to the exercised share Options plan ...
GENSCRIPT BIO (01548) issued 0.6 million shares on December 31 according to the exercised share Options plan.
GENSCRIPT BIO (01548) announced that on December 31, 2024, according to the information from July 1, 2015...
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
GENSCRIPT BIO (01548.HK) exercises the conversion rights of the convertible Bonds issued by Probio Cayman.
Gelonghui, December 20 - GENSCRIPT BIO (01548.HK) announced that the company's indirect non-wholly-owned subsidiary, Probio Technology Limited ("Probio Cayman"), has completed Series A financing and that the company has subscribed to the convertible Bonds issued by Probio Cayman. On December 20, 2024, based on the convertible Bonds instrument dated August 24, 2021 (as amended by the revised agreement dated December 18, 2024), the company will exercise its rights to invest $70 million.
Is Genscript Biotech (HKG:1548) Using Too Much Debt?
GenScript Announces 4th Annual Biotech Global Forum in San Francisco
Genscript Biotech Corporation's (HKG:1548) P/S Is Still On The Mark Following 29% Share Price Bounce
No Data
